• Optimi Health completed its first export of naturally derived psilocybin to the UK to supply a planned Phase 2 clinical trial.
• Shipment included psilocybin biomass, finished 5 mg capsules made at its GMP facility in Princeton, British Columbia.
• Move expands its international clinical-trial supply footprint, leveraging the same capsule formulation used in Australia for treatment-resistant depression.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Optimi Health Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606100915PRIMZONEFULLFEED9734471) on June 10, 2026, and is solely responsible for the information contained therein.